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Abstract
The combined treatment with histone deacetylase inhibitors (HDACi) and retinoids has been suggested as a potential epige-
netic strategy for the control of cancer. In the present study, we investigated the effects of treatment with butyrate, a dietary 
HDACi, combined with vitamin A on MCF-7 human breast cancer cells. Cell proliferation was evaluated by the crystal violet 
staining method. MCF-7 cells were plated at 5 x 104 cells/mL and treated with butyrate (1 mM) alone or combined with vitamin 
A (10 µM) for 24 to 120 h. Cell proliferation inhibition was 34, 10 and 46% following treatment with butyrate, vitamin A and their 
combination, respectively, suggesting that vitamin A potentiated the inhibitory activities of butyrate. Furthermore, exposure to 
this short-chain fatty acid increased the level of histone H3K9 acetylation by 9.5-fold (Western blot), but not of H4K16, and 
increased the expression levels of p21WAF1 by 2.7-fold (Western blot) and of RARβ by 2.0-fold (quantitative real-time PCR). 
Our data show that RARβ may represent a molecular target for butyrate in breast cancer cells. Due to its effectiveness as a 
dietary HDACi, butyrate should be considered for use in combinatorial strategies with more active retinoids, especially in breast 
cancers in which RARβ is epigenetically altered.
Key words: Breast cancer; MCF-7 cells; Butyric acid; Vitamin A; Epigenetics 
Introduction
Correspondence: T.P. Ong, Departamento de Alimentos e Nutrição Experimental, Faculdade de Ciências Farmacêuticas, USP, 
Av. Prof. Lineu Prestes, 580, Bloco 14, 05508-900 São Paulo, SP, Brasil. Fax: +55-11-3815-4410. E-mail: tong@usp.br
Received December 1, 2011. Accepted May 28, 2012. Available online June 22, 2012. Published August 17, 2012.
Breast cancer is the second leading cause of death by 
cancer in women globally and each year approximately 1 
million new cases of this disease are diagnosed (1). Thus, 
novel approaches to the prevention and treatment of breast 
cancer are imperative (2).
Deregulation of epigenetic mechanisms, such as DNA 
methylation and post-translational modifications of histones, 
has been implicated in breast carcinogenesis due to the 
observed silencing of critical tumor suppressor genes (3). In 
contrast to genetic alterations, epigenetic modifications are 
potentially reversible and have been identified as relevant 
molecular targets for cancer prevention and treatment (4). 
Bioactive food components exhibiting anticancer potential 
have been shown to modulate DNA methylation and his-
tone acetylation (5,6) in both in vitro and in vivo systems. 
Reactivation of epigenetically silenced genes by dietary 
components could potentially have important implications 
for cancer control strategies (7).
Among the dietary histone deacetylase inhibitors 
(HDACi), butyrate (BT) is of primary interest because of 
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its anticancer potential (8,9) and because it has already 
been tested for the treatment of cancer in phase I clinical 
trials (10,11). This short-chain fatty acid is produced by the 
fermentation of non-digestible dietary carbohydrates by 
intestinal bacteria and is also present in honey and milk fat 
(12). BT represents a promising candidate for the control of 
breast cancer progression (13,14). Previous studies have 
demonstrated that BT treatment inhibits the growth of breast 
cancer cell lines by acting as an HDACi and by inducing 
the expression of several genes, including cyclin-dependent 
kinase inhibitor p21 (14-16).
Vitamin A (VA; retinol) is an essential nutrient that regu-
lates several cellular processes, including growth, death and 
differentiation, and is known to be frequently deregulated 
during carcinogenesis. A majority of the functions exhibited 
by VA are exerted by its conversion to retinoic acid, which 
modulates gene expression by activating retinoic acid 
receptors (RARs) and retinoid X receptors. Due to these 
properties, VA has been considered for the treatment and 
prevention of breast cancer (17). An important limitation of 
its therapeutic application, however, involves the deregula-
tion of retinol metabolism in breast cancer cells that lack the 
ability to produce retinyl esters and thus to store VA (18). 
At the molecular level, this aberrant metabolism has been 
associated with epigenetic down-regulation of the tumor 
suppressor genes RARβ and cellular retinol-binding protein I 
(CRBP-I) (19-21). CRBP-I is responsible for the intracellular 
transport, esterification and oxidation of retinol (22).
The combination of an HDACi and retinoids represents a 
potential epigenetic strategy for cancer control (23), although 
few studies have addressed its efficacy in the context of 
breast cancer. In a previous study, retinoic acid treatment 
potentiated the inhibitory effects of the synthetic HDACi 
trichostatin on breast cancer cells in vitro and in vivo (24). 
More specifically, reactivation of RARβ expression induced 
by the synthetic HDACi increased the susceptibility of these 
cells to the inhibitory activities of retinoic acid (24). Based 
on these studies, we investigated the effects of the dietary 
HDACi BT alone and in combination with VA on estrogen 
receptor-α-positive MCF-7 human breast cancer cells. 
To assess the efficacy of these treatments, we evaluated 
several parameters such as cell proliferation, histone H3K9 
and H4K16 acetylation patterns, global DNA methylation 
patterns, RARß and CRBP-I gene and p21 protein expres-
sion, RARß gene promoter methylation, and intracellular 
retinoid levels.
Material and Methods
Cell culture and solution preparation
The MCF-7 human breast cancer cell line (HTB 22, 
American Type Culture Collection, USA) was grown in 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco, USA) 
supplemented with 10% fetal bovine serum (Gibco) at 37°C 
in a 5% CO2/air atmosphere. VA (retinyl palmitate; BASF, 
Germany) was dissolved in ethanol to produce 30 mM 
solutions. Further dilutions were made in culture medium 
to a final working solution of 10 µM VA containing 0.035% 
(v/v) ethanol. The VA solution was prepared immediately 
before use for each experiment. BT (sodium butyrate; 
Sigma-Aldrich, USA) was dissolved in culture medium to 
produce stock solutions of 0.5 M. Further dilutions were 
made in culture medium to achieve a final concentration 
of 1 mM BT. To control for the residual concentration of 
ethanol (0.035%, v/v) in the culture medium in the 10-µM 
VA working solution, ethanol was added to the culture 
medium, at this same concentration, of both BT-treated 
and control cells.
Cell proliferation assays
MCF-7 cells were plated at 5 x 104 cells/mL onto 96-well 
plates and incubated for 24 h. Cells were then treated with 
BT (0.5, 1, 2, 3, 4, and 5 mM) or VA (1, 5, 10, 15, and 20 
µM) and incubated for 24 to 120 h. Next, the combinato-
rial effects of BT and VA on MCF-7 cell proliferation were 
evaluated. Cells were treated with 1 mM BT and 10 µM VA, 
individually or combined, and incubated with the treatments 
for 24 to 120 h. Following incubation, cell proliferation was 
evaluated by the crystal violet staining method. Data are 
reported as means ± SEM.
Cell cycle analysis by cell cytometry
MCF-7 cells were plated at a density of 1 x 105 cells/
mL, treated with 1 mM BT and 10 µM VA, individually 
or combined, and incubated for 24 to 120 h. Following 
trypsinization, the harvested cells were resuspended with 1 
mL chilled phosphate-buffered saline (PBS; 137 mM NaCl; 
10 mM Na2HPO4; 2.68 mM KCl; 1.76 mM KH2PO4) and 
permeabilized with 3 mL chilled 100% methanol overnight. 
Afterwards the cells were centrifuged at 160 g for 5 min 
and washed with 1 mL PBS. The pellet was resuspended 
in 200 µL PBS containing propidium iodide (10 µg/mL) and 
RNase (10 mg/mL) and incubated for 1 h. The DNA content 
of the cells was then analyzed with a FACS CANTO II flow 
cytometer (BD Biosciences, USA).
Western blot analysis 
Acetylation of H3K9 and H4K16. MCF-7 cells were 
plated at a density of 1 x 105 cells/mL, treated with 1 mM 
BT and 10 µM VA, individually or combined, and incubated 
for 96 and 120 h. Following these incubation periods, cells 
were harvested and subjected to histone acid extraction 
as previously described by Jeong et al. (25). Total histone 
extracts were separated on a 15% denaturing polyacryl-
amide gel (SDS-PAGE). Proteins were transferred to 
Hybond-ECL membranes (GE Healthcare, Sweden) that 
were blocked with the ECL Advance Chemiluminescence 
kit (GE Healthcare) for 1 h at room temperature. Incubation 
with anti-acetyl-histone H3K9 or H4K16 primary antibody 
(1:5000; Upstate Biotechnology, USA) was carried out at 
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4°C overnight, and incubation with the secondary antibody 
conjugated to horseradish peroxidase (1:10,000; GE Health-
care) was carried out at room temperature for 1 h. Subse-
quently, membranes were incubated with primary anti-H1 
antibody (1:5000; Upstate Biotechnology) for 1 h at 37°C and 
then incubated with the secondary antibody conjugated to 
horseradish peroxidase (1:10,000; GE Healthcare) at room 
temperature for 1 h. Membranes were developed using the 
ECL Advance Chemiluminescence kit (GE Healthcare), 
and bands were revealed with the ImageQuant 400 capture 
imaging system (GE Healthcare). Protein bands detected 
at 11, 17, and 30 kDa corresponded to the expected mo-
lecular weight of histone H4, H3, and H1, respectively. 
A BIO-RAD densitometer (Imaging Densitometer Model 
GS-700, USA) with specific software (Molecular Analyst, 
USA) was used to quantify band intensities. To control 
for unequal protein loading, expression of the proteins of 
interest was normalized to the H1 signal (26).
p21WAF1 expression. MCF-7 cells were plated at a den-
sity of 1 x 105 cells/mL, treated with 1 mM BT and 10 µM 
VA, individually or combined, and incubated for 96 and 120 
h. Cells were harvested and subjected to protein extraction 
with the T-PER® Tissue Protein Extraction Reagent (Pierce, 
USA), according to the manufacturer protocol. Western 
blotting was performed as described for the H3K9 and 
H4K16 acetylation analyses. Proteins were incubated with 
primary anti-p21WAF1 antibody (1:1000; Santa Cruz Biotech-
nology, USA) at 4°C overnight and then incubated with a 
secondary antibody conjugated to horseradish peroxidase 
(1:10,000; GE Healthcare) at room temperature for 1 h. 
Subsequently, membranes were incubated with a primary 
anti-β-actin antibody (1:5000; Santa Cruz) for 1 h at 37°C 
and then incubated with a secondary antibody conjugated 
to horseradish peroxidase (1:10,000; GE Healthcare) at 
room temperature for 1 h. The resulting bands of 21 and 
40 kDa, corresponding to the expected molecular weight 
of p21WAF1 and β-actin, respectively, were quantified as 
previously described. To control for unequal protein load-
ing, expression of the protein of interest was normalized 
to the β-actin signal (14).
Dot blot analysis 
Dot blot analysis was performed as described by Al-
yaqoub et al. (27). MCF-7 cells were plated at a density 
of 1 x 105 cells/mL and treated with 1 mM BT and 10 µM 
VA, individually or combined, for 96 and 120 h. Cells were 
harvested and subjected to DNA extraction. DNA was 
isolated from MCF-7 cells by digestion with RNase A and 
proteinase K followed by organic extraction with phenol 
and chloroform. Purified DNA (2 µg) was denatured in 200 
µL 10 x 0.1 N NaOH/SSC buffer (3 M NaCl; 0.3 M sodium 
citrate, pH 7.0) at 95°C for 5 min and dotted onto Hybond-
ECL membranes (GE Healthcare). Membranes were dried, 
incubated with 5% milk in a solution of PBS + Tween-20 for 
2 h and then incubated with primary anti-5-methylcytosine 
antibody (1:1000; Megabase Research Products, USA) 
for 2 h. Following this incubation step, membranes were 
washed 3 times with the PBS + Tween-20 solution for 10 
min and incubated with a secondary antibody conjugated 
to horseradish peroxidase (1:20,000; GE Healthcare) for 
2 h at room temperature. After additional washing with the 
PBS + Tween-20, membranes were treated with detection 
reagents of the ECL Chemiluminescence kit (GE Health-
care) and exposed to Kodak autoradiography films. The 
absorbance of the dots was quantified using a BIO-RAD 
densitometer (Imaging Densitometer, Model GS-700) with 
specific software (Molecular Analyst). Previous staining 
of the nitrocellulose membrane with methylene blue was 
performed to control for the relative amount of DNA.
Quantitative real-time PCR analysis 
MCF-7 cells were plated at a density of 1 x 105 cells/
mL, treated with 1 mM BT and 10 µM VA, individually or 
combined, incubated for 96 and 120 h, and then harvested. 
RNA extraction was performed with the illustra RNAspin 
Mini RNA isolation kit (GE Healthcare, Germany), according 
to the manufacturer protocol. RNA quality was assessed 
by gel electrophoresis. Approximately 1 µg of total RNA 
was used for the synthesis of first-strand cDNA using the 
SuperScript™ First-Strand Synthesis System for RT-PCR 
(Invitrogen, USA) according to manufacturer instructions. 
Quantitative PCR analysis was performed in replicates 
using TaqMan chemistry and Assays on Demand probes 
(Applied Biosystems, USA) for RARβ (Hs00233407-m1) 
and CRBP-I (Hs01011514-m1). GAPDH (Hs99999905-m1) 
was used as a control. mRNA levels were quantified using 
the ABI Prism 7000 Sequence Detection System (Applied 
Biosystems). Amplification reactions were performed with 
a three-step thermal cycling method consisting of a 2-min 
step at 50°C, 10-min step at 95°C, and a final step of 50 
cycles at 95°C for 15 s and 60°C for 1 min.
Methylation-specific PCR analysis 
To analyze the methylation pattern of the RARβ gene 
promoter region, bisulfite modification of genomic DNA 
was assessed by methods similar to those described 
by Goldenberg et al. (28). The primers used for PCR 
were specific for the methylated and unmethylated DNA 
sequence. A volume of 2 µL modified DNA was used in 
the PCR assay with 5 µL 10X RT-PCR buffer (2.5 mM 
MgCl2 final concentration), 1 µL dNTP mix (10 mM of each 
dNTP), 1 µL forward and reverse primers (10 mM), 1.25 
U Platinum Taq DNA Polymerase and PCR grade water 
making up a total volume of 50 µL. The primer pairs were 
previously described by Esteller et al. (19): unmethylated 
sequence (5’-TTGGGATGTTGAGAATGTGAGTGATTT-3’ 
sense and 5’-CTTACTCAACCAATCCAACCAAAACAA 
3’ antisense) and methylated sequence (5’-TGTCGAG 
AACGCGAGCGATTC-3’ sense and 5’-CGACCA ATCCAA 
CCGAAACGA-3’ antisense). The PCR conditions were as 
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follows: 95°C for 5 min followed by 40 cycles of 94°C for 30 
s, 58°C for 1 min, and 72°C for 30 s, with a final extension 
of 72°C for 5 min. The PCR products were separated on 
2% agarose gels, and DNA was visualized with Blue Green 
(LGC Biotechnology, Brazil) staining.
HPLC analysis
MCF-7 cells were plated at a density of 1 x 105 cells/
mL, treated with 1 mM BT or 10 µM VA, or the combina-
tion of both compounds, incubated for 96 and 120 h, and 
then harvested. HPLC was carried out according to Murray 
et al. (29). Samples were analyzed by chromatography 
(Shimadzu model LC9A, Japan) using a C18 reverse-
phase column (CLC-ODS; 4.6 mm x 25 cm x 0.5 mm). The 
chromatograph consisted of a multisolvent pump system, 
an auto-injector (model SIL-6B) and a photodiode array 
UV-VIS detector (model SPD-M6A). The substances were 
eluted at a flow rate of 1.5 mL/min in a mobile phase con-
sisting of acetonitrile, dichloromethane and methanol at a 
20:20:10 ratio, respectively. Retinoids (retinol and retinyl 
palmitate) were detected at 325 nm and were identified on 
the basis of comparisons of their retention times and those 
of authentic standards. These compounds were quantified 
on the basis of peak areas.
Statistical analysis
Data are reported as means ± SEM, and all analyses 
were carried out with the Statistica 8.0 software (Statsoft, 
USA). Depending on the type of data, either one-way analy-
sis of variance followed by the Tukey or Duncan post hoc 
test or the Kruskal Wallis test was applied. For all analyses, 
the level of significance was set at P ≤ 0.05.
Results
Cell proliferation
Figures 1A and B depict the BT and VA dose-response 
effects on MCF-7 cell proliferation, respectively. Relative to 
controls, 5 mM BT-treated cells demonstrated significantly 
lower (P ≤ 0.05) cell proliferation from 48 to 120 h. The other 
BT concentrations (0.5-4 mM) showed lower (P ≤ 0.05) 
MCF-7 cell proliferation only after 120 h. Relative to control, 
20 µM VA-treated cells demonstrated lower (P ≤ 0.05) cell 
proliferation after 120 h. The other VA concentrations (1-15 
µM) did not reduce MCF-7 cell proliferation at any time. 
For the evaluation of the effects of combined treatment 
with BT and VA on MCF-7 cells, we selected doses that 
yielded intermediate cell proliferation inhibition in order to 
allow potential interactions between the dietary HDACi and 
the retinoid. Figure 1C depicts the results obtained after 
treatment with 1 mM BT and/or 10 µM VA. After 24 h of 
treatment, no differences was observed between control 
cells and cells subjected to the different treatments. Relative 
to controls, BT-treated cells showed lower (P ≤ 0.05) cell 
proliferation only after 72 h of treatment, whereas VA-treated 
cells did not differ from control at any time point. Compared 
to control, BT+VA-treated cells showed lower (P ≤ 0.05) cell 
proliferation after 48, 72, 96, and 120 h of treatment. Follow-
Figure 1. Effect of treatment with butyrate and/or vitamin A on 
MCF-7 cell proliferation evaluated by the crystal violet staining 
method (absorbance at 570 nm). A, MCF-7 cells treated with bu-
tyrate (BT; 0.5-5 mM); B, MCF-7 cells treated with vitamin A (VA; 
1-20 µM); C, MCF-7 cells treated with butyrate (BT; 1 mM) and/
or vitamin A (VA; 10 μM). Data are reported as means ± SEM. 
Three independent experiments were performed with N = 6 for 
each treatment. aP ≤ 0.5 for 5 mM BT treatment in A, 20 µM VA 
treatment in B and BT+VA treatment in C compared to respec-
tive controls; bP ≤ 0.5 for 0.5-4.0 mM BT treatments in A and BT 
treatment alone in C compared to respective controls (ANOVA 
followed by the Tukey test).
Efficacy of butyrate and vitamin A in breast cancer 845
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ing 120 h of BT, VA and BT+VA treatments, cell proliferation 
was inhibited by 34, 10 and 46%, respectively. These data 
suggest that VA may have potentiated the inhibitory effects 
of BT on MCF-7 cell proliferation.
Cell cycle profile
Figure 2 illustrates the cell cycle profile of MCF-7 cells 
treated with 1 mM BT and/or 10 µM VA for 48 h. BT+VA 
treatment decreased (P ≤ 0.05) and increased (P ≤ 0.05) 
the percentage of cells in the G0/G1 and G2/M phases, 
respectively. No differences were observed between treat-
ments during the other periods (24, 72, 96, and 120 h; data 
not shown).
Acetylation of H3K9 and H4K16
Figure 3 illustrates the results of H3K9 acetylation in 
MCF-7 cells treated with 1 mM BT and/or 10 µM VA for 
96 and 120 h. The 96-h treatment of MCF-7 cells with BT 
alone or in combination with VA resulted in a 9.5- and 8.0-
fold increase (P ≤ 0.05), respectively, in H3K9 acetylation 
relative to control. This increase was not observed when 
cells were treated with VA alone. No differences in H3K9 
acetylation were observed between BT- and BT+VA-treated 
cells. The 120-h treatment with BT and/or VA did not alter 
H3K9 acetylation compared to control. None of the treat-
ments assessed resulted in altered H4K16 acetylation 
(data not shown).
p21WAF1 expression
Figure 4 depicts p21WAF1 protein expression in MCF-
7 cells treated with 1 mM BT and/or 10 µM VA for 96 and 
120 h. Following 96 h of exposure, none of the treatment 
groups expressed altered p21WAF1 compared to control. 
The 120-h treatment with BT increased p21WAF1 expression 
by 3.8-fold (P ≤ 0.05) and 2.7-fold (P = 0.054) relative to 
VA-treated and control cells, respectively. VA and BT+VA 
treatments did not result in altered p21WAF1 expression 
compared to control. 
Global DNA methylation patterns 
Figure 5 illustrates the result of global DNA methylation 
pattern for MCF-7 cells treated with 1 mM BT and/or 10 
Figure 2. Effect of 48-h treatment with butyrate (BT) and/or vitamin A (VA) on MCF-7 cell cycle phases. Cell cycle profiles were ana-
lyzed by flow cytometry and the percentages of the cells in the G0/G1, S, and G2/M phases were calculated. The data are representa-
tive of three independent experiments. aP ≤ 0.5 for BT+VA treatment compared to control (ANOVA followed by the Tukey test).
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Figure 3. Effect of treatment with butyrate (BT) and/or vitamin A (VA) on H3K9 acetylation. Western blot analysis of H3K9 acety-
lation for MCF-7 cells treated or not with BT and VA, individually or combined, for 96 (A) and 120 h (B). Quantitation of histone 
H3K9 acetylation in MCF-7 cells treated or not with BT and VA, individually or combined, for 96 (C) and 120 h (D). The data are 
representative of three independent experiments and are reported as means ± SEM. aP ≤ 0.5 compared to control; bP ≤ 0.5 com-
pared to treatment with VA (ANOVA followed by the Tukey test).
Figure 4. Effect of treatment with butyrate (BT) and/or vitamin A (VA) on p21WAF expression. Western blot analysis of p21WAF 
expression was carried out in MCF-7 cells treated or not with BT and VA, individually or combined, for 96 (A) and 120 h (B). Quan-
titation of p21WAF expression in MCF-7 cells treated or not with BT and VA, individually or combined, for 96 (C) and 120 h (D). 
The data are representative of four independent experiments and are reported as means ± SEM. aP ≤ 0.5 compared to control; 
bP ≤ 0.5 compared to treatment with VA (ANOVA followed by the Duncan test).
Efficacy of butyrate and vitamin A in breast cancer 847
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µM VA for 96 and 120 h. 
Relative to control, 96- and 
120-h treatments with VA 
and BT+VA did not alter 
the global DNA methylation 
patterns.
RARβ and CRBP-I 
expression
Figure 6 provides RARβ 
expression data for MCF-7 
cells treated for 96 and 120 
h with 1 mM BT and/or 10 
µM VA. Relative to control, 
BT and/or VA treatments 
did not alter RARβ gene 
expression after 96 h. Compared to treatment with VA, BT 
treatment resulted in a 1.6-fold increase in the expression 
of this gene (P ≤ 0.05). Following 120 h of exposure, treat-
ments with BT alone or in combination with VA resulted 
in increased RARβ gene expression by 2.0- (P ≤ 0.05) 
and 1.7-fold (P ≤ 0.05), respectively, compared to control. 
The same increase was not observed in cells treated with 
VA alone. Treatment with BT resulted in increased RARβ 
gene expression by almost 2.0-fold (P ≤ 0.05) relative to 
VA-treated cells. No significant differences in RARβ gene 
Figure 5. Effect of treatment with butyrate (BT) and/or vitamin A (VA) on global DNA methylation. Dot-blot analyses for global 
DNA methylation patterns were determined in MCF-7 cells treated or not with BT and VA, individually or combined, for 96 (A) 
and 120 h (B). Membrane staining with methylene blue to control for unequal loading of total DNA of MCF-7 cells treated or 
not with BT and VA, individually or combined, for 96 (C) and 120 h (D). Quantitation of DNA methylation patterns in MCF-7 
cells treated or not with BT and VA, individually or combined, for 96 (E) and 120 h (F). The data are representative of three 
independent experiments conducted in duplicate and are reported as means ± SEM. No statistically significant differences were 
detected according to the Kruskal Wallis test (P > 0.05).
Figure 6. Effect of treatment with butyrate (BT) and/or vitamin A (VA) on RARβ expression. qPCR 
analyses of RARβ expression were carried out in MCF-7 cells treated with or without BT and VA, 
individually or combined, for 96 (A) and 120 h (B). The data are representative of four independent 
experiments and are reported as means ± SEM. aP ≤ 0.5 compared to controls; bP ≤ 0.5 compared 
to treatment with VA (ANOVA followed by the Tukey test).
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expression were observed between the BT and BT+VA 
treatment groups. Following 96 and 120 h of exposure, 
CRBP-I gene expression was not altered in any treatment 
group compared to control (data not shown).
Methylation of the RARβ promoter
Figure 7 depicts the methylation pattern of the RARß 
promoter in MCF-7 cells treated with 1 mM BT and/or 10 µM 
VA for 96 h. The RARβ promoter region was predominantly 
methylated in control MCF-7 cells and in cells treated with 
BT and/or VA.
Cellular levels of retinoids 
Figure 8 indicates the concentrations of retinol in MCF-7 
cells treated with 1 mM BT and/or 10 µM VA. Following 96 
h of exposure, no statistical differences in cellular concen-
trations of this retinoid were detected between treatments. 
After 120 h of exposure, only cells treated with VA alone 
demonstrated increased retinol concentrations (3.4-fold) 
(P ≤ 0.05) relative to control. Retinyl palmitate was not 
detected in control MCF-7 cells or in cells treated with BT 
and/or VA for 96 and 120 h.
Discussion 
Despite the anticancer potential of treatment with an 
HDACi combined with retinoids (23), few studies have ad-
dressed the potential of such interventions, specifically for 
the control of breast cancer. Efficacy of the combination 
of retinoic acid with the synthetic HDACis trichostatin (24) 
and valproic acid (30) was shown in breast cancer cells. 
Interestingly, our data showed that although VA did not 
inhibit MCF-7 cell proliferation, it seemed to potentiate 
inhibition of cell proliferation by BT. This combinatorial 
effect could involve arrest of MCF-7 cells in the G2/M 
phase. This reinforces the potential of combining the dietary 
HDACi BT with retinoids in the context of breast cancer. 
However, the BT and VA association did not present any 
combinatorial action on inhibition of proliferation of ER-
negative MDA-MB-231 human breast cancer cells (data 
not shown). This suggests that the type of breast cancer 
is a relevant issue that should be considered in anticancer 
combinatorial strategies with butyrate and retinoids. 
Treatment with BT alone or combined with VA resulted in 
similar increases in H3K9 acetylation, while H4K16 was not 
affected by either treatment. BT effects as an HDACi could 
involve modulation of specific histone residues. Importantly 
acetylated H3K9 seems to be a preferential site for histone 
acetyltransferase (31). Among HDACi targets, the cyclin-
dependent kinase inhibitor p21WAF1 has been of primary 
focus (32). As previously described (16), we observed that 
treatment with BT resulted in increased p21WAF1 expression 
in MCF-7 cells, suggesting that its HDACi activities may 
play a relevant role in its anticancer properties.
Global DNA hypomethylation leads to genomic instabil-
ity and activation of oncogenes (4). MCF-7 cells express 
a global hypomethylation compared to normal breast cells 
(MCF-10-2A) (33,34). In the present study, treatment with 
BT alone or combined with VA did not alter global DNA 
methylation patterns. Thus, BT anticancer actions do not 
seem to involve interference with this epigenetic process. 
Aberrant VA signaling has been associated with the pro-
gressive loss of RARβ2 expression (21) through epigenetic 
silencing by promoter hypermethylation (24,35). This epige-
Figure 7. Effect of treatment with butyrate (BT) and/or vitamin A (VA) on RARβ promoter methylation. MS-PCR analysis of RARβ 
promoter methylation was carried out in MCF-7 cells treated or not with BT and VA, individually or combined, for 96 h. The presence 
of the “U” product indicates the unmethylated RARβ gene. The presence of the “M” product indicates the methylated RARβ gene. 
H2O served as the negative control.
Figure 8. Effect of treatment with butyrate (BT) and/or vitamin 
A (VA) on retinoid levels. HPLC quantitation of retinol in MCF-7 
cells treated or not with BT and VA, individually or combined, for 
96 and 120 h. The data are representative of four independent 
experiments and are reported as means ± SEM. aP ≤ 0.05 com-
pared to control (ANOVA followed by the Tukey test).
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netic deregulation is known to contribute to breast cancer 
development and progression (36,37). In the present study, 
we observed that, despite the predominantly hypermethy-
lated state of the RARβ promoter in MCF-7 cells, treatment 
with BT alone or combined with VA could moderately induce 
the expression of this gene, suggesting that RARβ may 
represent a molecular target for BT in breast cancer cells. 
Due to its effectiveness as a dietary HDACi, BT should be 
considered for use in combinatorial strategies with more 
active retinoids, especially in breast cancers in which RARβ 
is epigenetically altered. The possibility of achieving more 
synergistic anticancer interactions with these interventions 
remains to be further elucidated.
We confirmed further that CRBP-I is down-regulated in 
MCF-7 cells (19,20,38). Contrary to what was hypothesized, 
however, the combination of BT with VA could not reactivate 
CRBP-I expression and this could provide a molecular 
explanation of why this intervention could not restore VA 
metabolism in MCF-7 cells, as evidenced by lack of storage 
of retinol as retinyl palmitate. 
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